|
Patent landscape, scope, and claims: |
Patent Analysis: U.S. Patent No. 7,122,566
U.S. Patent No. 7,122,566, titled "Methods for Treating Cancer," was granted on October 17, 2006. The patent claims methods of treating various cancers using a specific pharmaceutical composition. It is assigned to Celgene Corporation, now a subsidiary of Bristol Myers Squibb.
What is the Core Technology Protected by U.S. Patent 7,122,566?
The patent protects methods for treating cancer. Specifically, it claims the use of a combination therapy involving thalidomide or its analogs with at least one other chemotherapeutic agent. The claimed cancers include multiple myeloma, Kaposi's sarcoma, and lymphomas.
What are the Specific Claims of Patent 7,122,566?
The patent comprises multiple claims, with Claim 1 being the broadest. Key claims are detailed below:
- Claim 1: A method of treating a patient having a plasma cell neoplasm, comprising administering to the patient a therapeutically effective amount of thalidomide and at least one additional chemotherapeutic agent.
- Claim 2: The method of claim 1, wherein the plasma cell neoplasm is multiple myeloma.
- Claim 3: The method of claim 1, wherein the at least one additional chemotherapeutic agent is selected from the group consisting of a corticosteroid, an alkylating agent, an anthracycline, a platinum-based drug, a vinca alkaloid, and an epipodophyllotoxin.
- Claim 4: The method of claim 3, wherein the corticosteroid is dexamethasone.
- Claim 5: The method of claim 1, wherein the patient is administered a therapeutically effective amount of thalidomide, dexamethasone, and melphalan.
- Claim 6: A method of treating a patient having Kaposi's sarcoma, comprising administering to the patient a therapeutically effective amount of thalidomide and at least one additional chemotherapeutic agent.
- Claim 7: The method of claim 6, wherein the at least one additional chemotherapeutic agent is selected from the group consisting of a corticosteroid, an alkylating agent, an anthracycline, a platinum-based drug, a vinca alkaloid, and an epipodophyllotoxin.
- Claim 8: The method of claim 7, wherein the corticosteroid is dexamethasone.
- Claim 9: A method of treating a patient having a lymphoma, comprising administering to the patient a therapeutically effective amount of thalidomide and at least one additional chemotherapeutic agent.
- Claim 10: The method of claim 9, wherein the at least one additional chemotherapeutic agent is selected from the group consisting of a corticosteroid, an alkylating agent, an anthracycline, a platinum-based drug, a vinca alkaloid, and an epipodophyllotoxin.
- Claim 11: The method of claim 10, wherein the corticosteroid is dexamethasone.
- Claim 12: A method of treating a patient having a plasma cell neoplasm, comprising administering to the patient a therapeutically effective amount of a thalidomide analog and at least one additional chemotherapeutic agent.
- Claim 13: The method of claim 12, wherein the plasma cell neoplasm is multiple myeloma.
- Claim 14: The method of claim 12, wherein the at least one additional chemotherapeutic agent is selected from the group consisting of a corticosteroid, an alkylating agent, an anthracycline, a platinum-based drug, a vinca alkaloid, and an epipodophyllotoxin.
- Claim 15: The method of claim 14, wherein the corticosteroid is dexamethasone.
- Claim 16: The method of claim 12, wherein the patient is administered a therapeutically effective amount of a thalidomide analog, dexamethasone, and melphalan.
The patent also includes dependent claims that further define specific dosages, administration schedules, and combinations. The core of the invention lies in the synergistic effect of combining thalidomide or its analogs with other cancer drugs.
What is the Composition of Matter Protected by Patent 7,122,566?
This patent does not claim a novel composition of matter. Instead, it claims methods of using existing compounds, specifically thalidomide and its analogs, in combination with other known chemotherapeutic agents. Thalidomide itself was known prior to the filing of this patent. The novelty and inventiveness reside in the discovered therapeutic application through combination therapy for specific cancers.
What is the Patent Landscape Surrounding U.S. Patent 7,122,566?
The patent landscape for treatments involving thalidomide, particularly for multiple myeloma, is complex and competitive. U.S. Patent 7,122,566 is part of a broader intellectual property strategy related to thalidomide and its derivatives. Key aspects of the landscape include:
- Earlier Patents: Patents covering the compound thalidomide itself and its initial uses were filed and granted decades prior to U.S. Patent 7,122,566.
- Later Patents: Celgene and its successors have filed numerous patents related to:
- Analogs of Thalidomide: Compounds with similar structures but improved efficacy, safety profiles, or pharmacokinetic properties (e.g., lenalidomide, pomalidomide). These are often protected by distinct composition of matter patents.
- Specific Formulations: Novel drug delivery systems or formulations of thalidomide or its analogs.
- New Therapeutic Uses: Discovery of efficacy in treating other diseases or patient populations.
- Manufacturing Processes: Patented methods for synthesizing thalidomide or its derivatives.
- Generic Competition: As patents expire, particularly for the base compound thalidomide and its initial formulations, generic versions become available. However, patents covering specific analogs or novel uses can extend market exclusivity.
- Biosimil/Abbreviated New Drug Application (ANDA) Challenges: Competitors seeking to market generic versions of drugs derived from thalidomide often challenge existing patents through litigation.
The patent landscape is dynamic, with ongoing litigation and new patent filings aimed at extending market exclusivity for thalidomide-based therapies.
What are the Key Dates and Status of U.S. Patent 7,122,566?
- Application Filing Date: March 31, 2004
- Publication Date: October 14, 2004 (as US 2004/0198731 A1)
- Grant Date: October 17, 2006
- Original Expiration Date: March 31, 2024 (20 years from the filing date).
- Current Status: Expired. The patent expired on March 31, 2024.
What are the Primary Commercial Products Related to Patent 7,122,566?
While U.S. Patent 7,122,566 covers method of treatment claims, it is directly related to the commercialization of thalidomide-based therapies for cancer, most notably:
- Thalomid® (thalidomide): This is the primary branded drug associated with the methods claimed in U.S. Patent 7,122,566. It is indicated for the treatment of multiple myeloma and erythema nodosum leprosum. The patent claims cover the use of Thalomid in combination therapies that have become standard of care for multiple myeloma.
- Revlimid® (lenalidomide) and Pomalyst®/Imnovid® (pomalidomide): These are immunomodulatory drugs (IMiDs) developed by Celgene, which are analogs of thalidomide. While not directly claimed as compositions of matter by U.S. Patent 7,122,566, they are part of the same therapeutic class and often used in similar combination regimens. Patents covering these specific analogs have different expiration dates and grant broader protection.
The expiration of U.S. Patent 7,122,566 removes patent protection for the specific method of treatment claims for thalidomide in combination therapies for the listed cancers. This could potentially impact pricing and market entry for generic versions of combination therapies that exclusively relied on this patent for method of use protection, though other patents, particularly those on the active ingredients themselves or newer analogs, remain relevant.
What is the Geographic Scope of Patent 7,122,566?
The patent is a United States patent, providing protection only within the territorial limits of the United States. Protection in other countries would require corresponding patent filings in those jurisdictions.
What is the Impact of Patent 7,122,566 Expiration?
The expiration of U.S. Patent 7,122,566 on March 31, 2024, signifies the end of its 20-year term. This means that the specific method of treatment claims for using thalidomide in combination with other chemotherapeutic agents for multiple myeloma, Kaposi's sarcoma, and lymphomas are no longer exclusively held by the patent owner within the United States.
This expiration has the following potential impacts:
- Increased Generics: Pharmaceutical companies that previously faced patent-protected method claims may now be able to offer generic versions of combination therapies that utilize thalidomide for these indications.
- Pricing Pressure: The entry of generic alternatives can lead to significant price reductions for the combination treatments.
- Market Dynamics: The market for thalidomide-based cancer treatments may become more competitive, with a wider range of product offerings.
- Focus on Newer Analogs: The expiration might shift the focus to newer, still-patented thalidomide analogs (e.g., lenalidomide, pomalidomide) and their associated patents, which often have later expiration dates. These analogs may offer improved efficacy or safety profiles and are protected by their own distinct patent portfolios.
It is important to note that the expiration of this specific patent does not necessarily mean the end of all patent protection related to thalidomide therapies. Patents covering the composition of matter of thalidomide itself, its formulations, manufacturing processes, or later-developed analogs remain critical for market exclusivity.
Key Takeaways
- U.S. Patent No. 7,122,566 protected methods of treating multiple myeloma, Kaposi's sarcoma, and lymphomas by combining thalidomide or its analogs with other chemotherapeutic agents.
- The patent expired on March 31, 2024, removing method of use protection for these specific combination therapies within the United States.
- The expiration may facilitate the entry of generic combination therapies and increase market competition, potentially leading to price reductions.
- Patents covering thalidomide analogs like lenalidomide and pomalidomide, along with their respective compositions of matter and specific uses, remain active and continue to provide market exclusivity.
Frequently Asked Questions
-
Does the expiration of U.S. Patent 7,122,566 allow for the sale of generic thalidomide?
The patent's expiration removes method of treatment claims for specific combination therapies. Generic thalidomide itself may have been subject to earlier or different patent protections or has been available for certain indications post-patent expiry of its original composition of matter patent.
-
Will the price of cancer treatments using thalidomide decrease significantly due to this patent expiring?
The expiration can lead to price decreases by enabling generic competition for the specific combination methods claimed. However, the overall cost of treatment also depends on the patent status of other components in the combination therapy and the branded drugs utilizing more recent analogs.
-
Are there still patents protecting thalidomide-based drugs?
Yes, patents protecting specific thalidomide analogs (e.g., lenalidomide, pomalidomide), their compositions of matter, formulations, and newer therapeutic uses are distinct from U.S. Patent 7,122,566 and remain in force.
-
What specific cancers are covered by the method claims of U.S. Patent 7,122,566?
The patent covers methods for treating multiple myeloma, Kaposi's sarcoma, and lymphomas.
-
What is the relationship between U.S. Patent 7,122,566 and drugs like Revlimid®?
U.S. Patent 7,122,566 claims methods of treatment using thalidomide. Revlimid® (lenalidomide) is an analog of thalidomide and is protected by its own set of patents covering its composition of matter, specific uses, and formulations, which are separate from U.S. Patent 7,122,566.
Citations
[1] United States Patent 7,122,566. (2006). Methods for Treating Cancer. Issued October 17, 2006.
[2] U.S. Patent Application Publication No. US 2004/0198731 A1. (2004). Methods for Treating Cancer. Published October 14, 2004.
[3] United States Patent Database, USPTO.gov. Accessed October 26, 2023.
More… ↓
⤷ Start Trial
|
